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Isolated nodal failureBackground and purpose: Isolated nodal failures (INF) are rare after 3D-conformal radiotherapy (3D-CRT)
for stage III non-small cell lung cancer (NSCLC). Since incidental nodal irradiation doses are lower with
Intensity Modulated Radiation Therapy (IMRT) than with 3D-CRT, INF may be higher after IMRT. We
therefore investigated the incidence of INF after IMRT in stage III NSCLC patients.
Materials and methods: Stage III NSCLC patients undergoing radical radiotherapy using IMRT in the period
January 2010 till March 2012 were included. The primary endpoint was the rate of INF, secondary end-
points included patterns of failure, progression free survival (PFS), overall survival (OS) and toxicity.
Results: 183 stage III NSCLC patients were enrolled. With a median follow-up of 58.0 months 2.2% of
patients had an INF. The median PFS was 15.0 months, the median OS 19.5 months. Patterns of recur-
rence: 2.2% INF, 11.5% local and 2.7% loco-regional recurrence, 26.8% distant metastases only, 18.0% a
combination of local/loco-regional and distant metastases, and 38.3% patients without recurrence. One
INF was out of field, in adjacent lymph nodes. Acute toxicity was limited.
Discussion: Selective nodal irradiation using IMRT in stage III NSCLC patients results in a low in-field inci-
dence of INF (2.2%), similar to 3D-CRT, and may thus be considered safe.
 2016 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 121 (2016) 322–327Lung cancer is one of the most frequently diagnosed solid
tumours and the leading cause of cancer death [1,2]. Non-small cell
lung cancer (NSCLC) accounts for about 80% of all lung cancer
cases, and one third of the lung cancer patients presents with stage
III disease [3]. The treatment of choice for most patients with stage
III NSCLC is concurrent chemo-radiation [4–6].
Since local failure rates remain high after chemo-radiation, sev-
eral strategies have been investigated to further improve local
tumour control, including increasing the radiation dose [7,8]. The
volume of the primary tumour and lymph seems to be associated
with the probability of local and regional failure [9]. Selective
nodal irradiation (SNI) instead of elective nodal irradiation (ENI)gives the opportunity to increase total tumour dose by decreasing
the irradiated volume or to reduce toxicity [10–12]. Two prospec-
tive studies using 3D conformal radiotherapy (3D-CRT), in which
selective nodal irradiation was based on PET-CT using 18F-
fluorodeoxyglucose (FDG), showed only 2–2.3% isolated nodal fail-
ure (INF) [13,14]. Conversely, after ENI, INF ranged from 0.0 to 9.0%
of the patients [15–17]. One of the reasons for the low percentages
of INF with 3D-CRT may be the incidental dose given to adjacent
lymph nodes, which may effectively eradicate microscopic metas-
tases [15,18,19]. Other reasons may be that modern imaging and
non-invasive staging has improved to such an extent that the rate
of false negative nodes is so low that INF is a safe therapeutic strat-
egy or that chemotherapy has eradicated nodal metastases.
IMRT is increasingly used in daily practice [8,20–24]. Studies
suggest that IMRT in comparison to 3D-CRT delivers the dose more
conformal to the target volume with a lower dose to the organs at
risk [23,25–27]. However, IMRT leads to a significant lower inci-
dental dose to adjacent lymph nodes as shown by Fleckenstein
et al. [28]. If the adjacent lymph nodes contain microscopic metas-
tasis, this lower dose may lead to a higher incidence of INF.
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stations of 23.6% with IMRT compared to 27.3% with 3D-CRT [28].
We therefore investigated the INF-rate in stage III NSCLC patients
treated with IMRT.Materials and methods
Study population
This study was approved by the Institutional Review Board of
MAASTRO clinic (registration 13-18-17/07-intern-6915). For this
current analysis we selected all patientswhowere treatedwith rad-
ical intent (concurrent or sequential with chemotherapy or radio-
therapy (RT) alone) using IMRT in the period January 2010 till
March 2012. Patients receiving chemotherapy concurrent with RT
were included in a prospective observational study on the individu-
alization of radiation dose (NCT00572325). Patients eligible for this
analysis had histological and/or cytological confirmed stage IIIA and
IIIB (Union for International Cancer Control, TNM 7th edition)
NSCLC, less than10%weight loss in sixmonths, aWorldHealthOrga-
nization Performance Status (WHO-PS) of 0–2, a forced expiratory
volume in one second [FEV1]P 30% of the predicted value and a dif-
fusion capacity of lungs for carbon monoxide [DLCO], not corrected
for alveolar volumeP30%. Patientswere excluded fromthis analysis
if they had received surgery, or prior thoracic radiation.Treatment
Patients received chemotherapy concurrently (conCRT) or
sequentially (seqCRT) with RT or RT alone. In case of conCRT,
chemotherapy consisted of cisplatin-etoposide (cisplatin 75–
80 mg/m2 day 1, etoposide 100 mg/m2 day 1–3) or cisplatin-
vinorelbine (cisplatin 50 mg/m2 day 2 and 9, 40 mg/m2 day 23;
vinorelbine 20 mg/m2 day 2 and 9, 15 mg/m2 day 23 and 30) every
three weeks, administered with radiotherapy for three cycles.
Radiotherapy was intended to start no later than the first day of
the second cycle of chemotherapy. In case of seqCRT, chemother-
apy consisted of three courses of gemcitabine (1.250 mg/m2 on
days 1 and 8) in combination with cisplatin (75 mg/m2 on day 1)
every three weeks. For both regimens standard dose-reduction
rules were applied and cisplatin was substituted by carboplatin
in case of renal impairment.Radiotherapy
A FDG-PET-CT scan with low-dose CT for attenuation correction
and an intravenous (iv) contrast-enhanced 4D-CT scan (Truepoint
Biograph 40, Siemens, Erlangen, Germany) were performed for
radiation planning purposes, and the delineation was based on
fused imaging datasets. The total gross tumour volume (GTV)
consisted of the primary tumour (GTV-1) delineated on the
mid-ventilation CT scan fused with the PET-scan and the
FDG-PET-positive and/or cytological proven malignant lymph
nodes (GTV-2). A margin of 5 mm around the GTV was used to
create the clinical target volumes, which were corrected for
anatomical boundaries (CTV-1 and CTV-2, respectively). By adding
a 10 mm margin to the CTV-1 and a 5 mm margin to the CTV-2 the
planning target volume (PTV) was created. The volume of both
lungs minus the total GTV was used for the calculation of the mean
lung dose (MLD). Organs at risk were delineated: spinal cord (inner
margin of the bony spinal canal), the oesophagus (outer contour
from cricoid to gastro-oesophageal junction), brachial plexus and
mediastinal structures (including great vessels, trachea, main
bronchi and heart).
IMRT plans, were calculated according to the International
Commission on Radiation Units and Measurement (ICRU, reports50 and 62) standards using a superposition-convolution or an
AAA algorithm, for a CMS XiO Radiotherapy Treatment Planning
System (Xio, CMS, St Louis, MO).
Plans were optimized by direct machine parameter optimiza-
tion with seven to nine coplanar and a maximum of two non-
coplanar 6 and 10 MV photon beams based on the location of the
target volume. Every plan was created by using 10–15 segments
per beam and involved a maximum of 25–35 iterations. Dose gra-
dients in the PTV ranged from 90% to 115% (preferably 95% to
115%) of the prescribed dose, and 99% of the PTV ought to receive
at least 90% of the prescribed dose.
Patients were irradiated on a linear accelerator (Siemens Oncor,
Siemens Medical Solutions, Concord, CA) using Electronic Portal
Imaging Device (EPID) measurements for treatment verification.
The radiationdosewas individuallyescalated for all patientsuntil
one of the dose-limiting normal tissue constraints was reached: a
maximum MLD of 20.0 Gy, a maximum spinal cord dose (Dmax) of
54.0 Gy, a Dmax to the brachial plexus of 70.0 Gy, a Dmax to medi-
astinal structures of 76.0 Gy, mean dose (Dmean) to the heart of
46.0 Gy or a Dmax of 76.0 Gy to the oesophagus. With conCRT the
maximum allowed total tumour dose (TTD) was 69.0 Gy, delivered
in 1.5 Gy fractions twice daily up to 45.0 Gy, followed by 2-Gy frac-
tions once daily [29]. The maximum allowed TTD with seqCRT or
RT alone was 79.2 Gy, given in twice daily fractions of 1.8 Gy [30].
Patientswhowere unable or not fit to be irradiated twice daily,were
treatedwith once daily fractions of 2.75 Gywith amaximumTTD of
66.0 Gy.Constraintswere recalculatedto theequivalentdose in2-Gy
fractions (EQD2) and biological MLD [13,29,30].Endpoints
The primary endpoint of this analysis was INF, and the sec-
ondary endpoints were patterns of failure, OS, PFS and toxicity.
Follow-up was performed according to regional guidelines, con-
sisting of a CT-scan with IV contrast 3 months after (C)RT, followed
by regular X-rays of thorax and a yearly CT-scan. Additional imag-
ing e.g. FDG-PET-CT scan was performed if clinically indicated.
Imaging was used to determine local or regional disease progres-
sion or distant failure. If one or more of the following criteria were
met, we scored it as a nodal failure: 1. Lymph nodes that were
pathologically proven to contain malignant cells after radiother-
apy. 2. Enlarged lymphnode with increased uptake of 18F-
fluorodeoxyglucose on a FDG-PET-CT. 3. Lymph nodes that showed
more than 20% growth after radiotherapy.
In case of a local or regional recurrence, the diagnostic images
were compared with the radiation treatment plan. Local and nodal
recurrences were considered in field if at least part of the recur-
rence disease volume was inside the original CTV and out of field
if the recurrence was completely outside the original CTV. Out of
field nodal recurrences were subdivided as recurrences in adjacent
or non-adjacent lymph node stations, using the CT based atlas of
Chapet et al. [31].
INF was defined as a recurrence in the regional lymph nodes
without a synchronous local recurrence or distant metastases. Tox-
icity was scored according to the Common Terminology Criteria of
Adverse Events (CTCAE) v. 4.0 by the radiation oncologist before
start of radiotherapy, weekly during treatment and one month
after radiotherapy. Last follow-up was on December 12th, 2015.
The survival status was evaluated on December 15th, 2015 using
a decentralized population registration system containing infor-
mation about all inhabitants of the Netherlands.Statistical analysis
The null hypothesis is that IMRT does not lead to more INF than
3D-CRT. Baseline INF with 3DCRT is 2.5%. For the statistical
324 IMRT based selective nodal irradiation in NSCLCanalysis the SPSS software (IBM SPSS Statistics, Version 19.0, NY)
was used. Patterns of recurrence were analyzed: the incidence of
INF and the 2-year risk was calculated using the Kaplan–Meier
method and Life-table analysis. For comparison of different treat-
ment groups the Log-rank test was used.
OS was defined as the interval between pathological diagnosis
and death or last follow-up using the Kaplan–Meier method. PFS
was defined as the interval between pathological diagnosis and
imaging showing local or regional progression, or distant metas-
tases or death, whatever occurred first. For dyspnoea, cough and
dysphagia grade 3 or more crude incidences were calculated.
Results are expressed as mean or median ± standard deviation
(SD) or the 95% confidence interval (CI) and range.Results
Between January 2010 and March 2012 183 patients
(119 males and 64 females) with a median age of 68.0 ± 9.8 yearsTable 1
Patient, tumour and treatment characteristics.
Characteristics No. of patients (%)
concurrent






Male 73 (62.4) 32 (71.1)
Female 44 (37.6) 13 (28.9)
WHO PS
0 105 (89.7) 29 (64.4)
1 11 (9.4) 16 (35.6)
2 1 (0.9) 0
Histology
SCC 42 (35.9) 23 (51.1)
NSCLC NOS 32 (27.4) 10 (22.2)
Adenocarcinoma 27 (23.1) 9 (20.0)
Large cell 14 (12.0) 3 (6.7)
Other 2 (1.6) 0
Clinical stage
IIIA 59 (50.4) 22 (48.9)











TTD 79 (66.5) 29 (64.4)
MLD 23 (19.7) 10 (22.2)




Brachial plexus 2 (1.7) 0







WHO-PS =World Health Organisation Performance Score, GTV = total gross tumour
volume, TTD = total tumour dose, MLD = mean lung dose, OTT = overall treatment
time, SCC = squamous cell carcinoma, NOS = not otherwise specified.(range 34–88) were treated with IMRT. Patient, tumour and treat-
ment characteristics are presented in Table 1. Concurrent
chemotherapy was given in 117 patients (63.9%), while 45 patients
(24.6%) received induction chemotherapy followed by RT, and 21
patients (11.5%) received RT only. The median delivered TTD was
69.0 ± 9.3 Gy (1.5–73.8 Gy) in a median overall treatment time
(OTT) of 35.0 ± 9.2 days (1.0–56.0 days). The allowed maximum
dose of 69.0 Gy was prescribed in 63.4% of the patients, in the other
patients MLD was most often dose limiting (21.3%). The median
follow-up time was 58.0 months (95% CI 55.8–60.3).
Only four patients (2.2%) experienced an INF (actuarial 2-year
risk 2.4%; 95% CI 0.0–5.7) of which three were in field recurrences
and one was out of field. The patient with an out of field recurrence
originally had pathologic lymph nodes in 6, 5, 4L, 2L and 1L and
had a recurrence in 1R.
One hundred and twelve patients (61.2%) showed recurrent dis-
ease: 11.5% (n = 21) local recurrence, 2.7% (n = 5) loco-regional
recurrence, 26.8% (n = 49) distant metastases only and 18.0%
(n = 33) a combination of local/loco-regional recurrence and dis-
tant metastases. Of the local recurrences 85.7% was in field and
14.3% was out of field. Of all regional recurrences 63.3% was in field
and 36.7% out of field. Of those out of field nodal recurrences, 27.3%
(n = 3) occurred in an adjacent and 72.7% (n = 8) in non-adjacent
lymph node stations. An overview of the recurrences is presented
in Table 2.
At the time of analysis 140 patients (76.5%) had died. The med-
ian OS was 19.5 months (95% CI 16.3–22.8 months), with a 1-year
OS of 69.7% and a 2-year OS of 42.3% (actuarial 2-year OS 41.0%) for
the entire group as depicted in Fig. 1. For the conCRT group the
median OS was 20.8 months (95% CI 16.6–25.2 months) and
16.0 months (95% CI 10.8–21.2 months) for the seqCRT group
(p = 0.13). The latter might be an overestimations as patients
who had progressive disease after chemotherapy were excluded.
At the time of analysis, 112 patients (61.2%) had developed
recurrent disease. The median PFS was 15.0 months (95% CI
11.3–18.8 months) with a 1-year PFS of 60.0% and a 2-year PFS of
35.2% (actuarial 2-year PFS 35%) for the entire group (see Fig. 2).
For the conCRT group the median PFS was 14.1 months (95% CITable 2
Pattern of recurrences.




Out of field 4
Isolated nodal 4 (2.2)
In field 3
Out of field 1
Adjacent lymph node station 1
Non-adjacent lymph node station 0
Loco-regional, with regard to nodal recurrences 5 (2.7)
In field 3
Out of field 2
Adjacent lymph node station 0
Non-adjacent lymph node station 2
Distant metastases 49 (26.8)
Combination, with regard to nodal recurrences 33 (18.0)
In field 13
Out of field 8
Adjacent lymph node station 2
Non-adjacent lymph node station 6
Local = tumour recurrence, isolated nodal = nodal recurrence, loco-regional = tu-
mour and nodal recurrence, combination = distant metastases with tumour and/or
nodal recurrence.
Fig. 1. Kaplan–Meier curves showing Overall Survival (OS) for the entire cohort (a) and separated for concurrent, sequential and radiotherapy alone (b).
H.M.A. Martinussen et al. / Radiotherapy and Oncology 121 (2016) 322–327 3259.3–18.9 months) versus 15.7 months (95% CI 6.5–24.8 months) for
the seqCRT group (p = 0.63).
Before start of RT none of the patient had developed severe tox-
icity (Pgrade 3). During radiotherapy most patients had no (10.6%)
or only mild dysphagia (grade 1: 26.7%, grade 2: 47.2%), whereas in
15.5% of the patients grade 3 dysphagia occurred (conCRT 17.5%,
seqCRT 15.6%, RT alone 4.8%). One month after radiotherapy 17
patients had persistent severe dysphagia [15 patients (11.5%) grade3, two patients (1.5%) grade 4]. These complaints resolved in ele-
ven of these patients, the grade was unclear in three patients three
months after radiotherapy, and three patients died before reaching
three months after radiotherapy.
Severe dyspnoea was not observed during radiotherapy, but one
month after radiotherapy four patients (3.1%) suffered from grade
3 dyspnoea. Three of these patients died within four months after
radiotherapy and in one patient grade 3 dyspnoea persisted more
Fig. 2. Kaplan–Meier curve showing Progression Free Survival (PFS) for the entire cohort.
326 IMRT based selective nodal irradiation in NSCLCthan three months after radiotherapy. Of those patients with sev-
ere dyspnoea one patient had atrial fibrillation, pneumonia, cardiac
failure and lung fibrosis, in one patient a radiation pneumonitis
was suspected, lung fibrosis was the cause in another patient and
in one patient recurrent disease was suspected.Discussion
To the best of our knowledge, this is the first study investigating
the INF rate in NSCLC with selective nodal irradiation using IMRT.
Although it was previously shown that selective nodal RT in the
3D-CRT era resulted in an INF rate of about 2%, these achievements
may not be extrapolated to IMRT as the dose to adjacent lymph
nodes are lower. We observed an INF rate of 2.2% (actuarial 2-
year risk 2.4%; 95% CI 0.0–5.7), which is equal to INF after 3D-
CRT (2.0–2.3%). Previous studies have shown that selective nodal
irradiation does not result in a higher percentage INF in compar-
ison with elective nodal irradiation [13,14]. De Ruysscher et al.
[13] reported an INF of 2.0% in patients treated with selective nodal
irradiation using 3D-CRT. Comparable results were seen in a study
of Belderbos et al. [14] with an INF-rate of 2.3%. Also for locally
advanced small cell lung cancer (SCLC), selective nodal RT has pro-
ven to be safe. In a prospective study, van Loon et al. observed an
INF rate of 3%, which as similar to the 2% incidence in a retrospec-
tive series from MD Anderson [32,33]. In a larger study, Reymen
et al. found out field INF in 1.7% of the patients with SCLC [34].
We have not directly compared IMRT and 3D-CRT plans in our
study. However 3D-CRT plans consists usually of 3 photon beams
(AP, PA and lateral) whereas in the IMRT plan seven to nine copla-
nar and a maximum of two non-coplanar photon beams were used.
This leads to the IMRT plans being more conformal and giving a
lower dose to adjacent lymph nodes than 3D-CRT. Studies have
confirmed that IMRT gives a more conformal dose to the target vol-
ume with lower doses to the organs at risk [23,25–27]. Moreover
Fleckenstein et al. showed in their study that the dose to lymph
nodes adjacent to the CTV is significantly lower when IMRT iscompared to 3D-CRT which translates into a lower tumour control
probability [28].
The definition of INF differs between the studies. We defined an
INF as a nodal recurrence without local recurrence or distant
metastases. We considered out of field as outside the CTV, whereas
in other studies ‘‘out of field” was defined as outside of the PTV. In
the present study one INF was outside the CTV and outside the
PTV. We used the atlas of Chapet et al. [31] to assess recurrences
in specific lymph node levels. There could be anatomical changes
due to the radiotherapy but they seem less relevant in nodal recur-
rences as local recurrences would in the lung.
A portion of the patients in this study were treated with seqCRT.
Patients were included in this study at the day of the first radiation
fraction. If patients showed progression or if the WHO-PS declined
during the chemotherapy patients were not referred for radical
treatment and thereby not enrolled in this study. This might have
influenced outcome in the sequential group with regard to OS and
PFS, however we do not believe that it would have a great influence
on the incidence of isolated nodal failure.
The acute toxicity when using IMRT is comparable with the
acute toxicity using 3D-CRT.
Although FU was according to the regional guidelines, there
might have been some difference between the referring hospitals
regarding timing and manner of FU which could influence the tim-
ing of the nodal recurrence. Asymptomatic nodal recurrences could
have been missed or diagnosed on a later time point. Only seven
patients (3.8%) experienced a nodal recurrence with distant metas-
tases without a local recurrence. It can obviously not be excluded
that in these cases the nodal recurrence is the source of the distant
metastases.
Although the incidence of INF is limited, the addition of EBUS-
TBNA mapping and other imaging modalities may have additional
value to staging with FDG-PET-CT to further decrease the number
of geographical misses [35,36].
In conclusion, FDG-PET-CT based selective nodal irradiation
with IMRT results in an INF-rate of 2.2%, which is comparable to
INF-rates after 3D-CRT, and may thus be considered safe.
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